Krishna Anand Putta

Abstract 1701: EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic

P. Singh, S. Gullapalli, M. K. Gurjar, 2018, Immunology.